Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform the treatment of autoimmune diseases, including type 1 diabetes, and cancer by developing allogeneic, iPSC-derived cell therapies.
PRESS RELEASES + EVENTS
view all
October 14, 2026
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology…
October 02, 2026
Century Therapeutics’ CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical…
About us
We are building an industry-leading, allogeneic, iPSC-derived cell therapy platform for autoimmune diseases, including type 1 diabetes, and cancer.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
